shutterstock_2139553995_t_schneider

T. Schneider / Shutterstock.com

7 June 2022Big PharmaSarah Speight

Arbutus, Genevant reject Moderna’s vaccine patent defence

Moderna’s bid to avoid a COVID-19 patent claim has been rejected by two pharma companies that are suing the vaccine manufacturer for infringing its drug delivery technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

More on this story

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

More on this story

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York